The landscape of cancer treatment is continuously evolving, with targeted therapies playing an increasingly significant role. Among these, Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as powerful tools. The synthesis of these complex molecules often hinges on the availability of precise chemical building blocks, and 2-Fluoro-5-[(3-oxo-1(3H)-isobenzofuranylidene)methyl]-benzonitrile stands out as a key intermediate.

This compound, identified by CAS number 763114-25-6, is characterized by its unique fluorinated benzonitrile structure. Its specific arrangement of functional groups makes it an invaluable precursor in the multi-step synthesis of potent PARP inhibitors. For researchers and pharmaceutical manufacturers, obtaining this intermediate with high purity is non-negotiable. We, as a dedicated manufacturer and supplier, ensure that our 2-Fluoro-5-[(3-oxo-1(3H)-isobenzofuranylidene)methyl]-benzonitrile consistently meets a purity standard of over 98% via HPLC, which is critical for the efficacy and safety of the final drug product.

The importance of reliable sourcing cannot be overstated. When you need to buy this vital component for your Olaparib synthesis or other PARP inhibitor projects, choosing a manufacturer with a proven track record is essential. We offer competitive pricing and a stable supply chain, ensuring your research and production needs are met without compromise. If you are looking for a manufacturer that understands the intricacies of pharmaceutical intermediates, consider our capabilities.

Our commitment extends beyond just supplying a chemical; we aim to be a strategic partner in your drug development journey. By providing high-quality 2-Fluoro-5-[(3-oxo-1(3H)-isobenzofuranylidene)methyl]-benzonitrile, we help accelerate your progress towards bringing innovative cancer therapies to patients. For inquiries regarding availability, price, or bulk orders, we encourage you to connect with our sales team. We are ready to support your chemical sourcing requirements from our base in China.